2 options
Immune dysregulation in pancreatic cancer / Austin Patrick Joseph Huffman.
- Format:
- Book
- Thesis/Dissertation
- Author/Creator:
- Huffman, Austin Patrick Joseph, author.
- Language:
- English
- Subjects (All):
- Immunology.
- Oncology.
- Cellular biology.
- Health sciences.
- Pathology.
- Immunology--Penn dissertations.
- Penn dissertations--Immunology.
- Local Subjects:
- Immunology.
- Oncology.
- Cellular biology.
- Health sciences.
- Pathology.
- Immunology--Penn dissertations.
- Penn dissertations--Immunology.
- Genre:
- Academic theses.
- Physical Description:
- 1 online resource (147 pages)
- Contained In:
- Dissertations Abstracts International 82-04B.
- Place of Publication:
- [Philadelphia, Pennsylvania] : University of Pennsylvania ; Ann Arbor : ProQuest Dissertations & Theses, 2020.
- Language Note:
- English
- System Details:
- Mode of access: World Wide Web.
- text file
- Summary:
- The clinical success of immune checkpoint blockade (ICB) therapies in recent years has been remarkable. Yet most cancer patients, including entire disease types, do not respond to these agents. Pancreatic ductal adenocarcinoma (PDAC) is a common and lethal disease that does not respond to ICB treatment. Here, we demonstrate that immune dysregulation in the KPC mouse model of PDAC is mediated by a T-cell priming deficiency that begins in the earliest stages of oncogenesis. Furthermore, we show that systemic administration of a CD40 agonist reverses this T-cell priming deficiency. CD40 agonist has been shown to drive intratumoral T-cell infiltration and confer ICB-responsiveness to PDAC. This combination CD40/ICB therapy depends on CD4+ T-cells in both primary and re-challenge models. We demonstrate using single-cell transcriptomics that CD40/ICB therapy depends on the chemokine CCL5, which is upregulated across a range of myeloid cells within the tumor. CCL5 mediates the intratumoral influx of CD4+ T-cells in response to treatment, and this influx depends upon CCR5. Together, these studies describe the immune dysregulation of an ICB-resistant cancer and provide mechanistic insight into a clinically promising strategy to reverse that dysregulation.
- Notes:
- Source: Dissertations Abstracts International, Volume: 82-04, Section: B.
- Advisors: Laufer, Terri M.; Vonderheide, Robert H.; Committee members: Taku Kambayashi; Ben Stanger; E. Wherry.
- Department: Immunology.
- Ph.D. University of Pennsylvania 2020.
- Local Notes:
- School code: 0175
- ISBN:
- 9798672166094
- Access Restriction:
- Restricted for use by site license.
- This item must not be sold to any third party vendors.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.